Chasing Bristol Myers and Biogen/Denali, CNS biotech raises $100M in dash toward clinic
In the months after South San Francisco-based Neuron23 announced a combined Series A and Series B, the biotech sat back down at the negotiating table for more funding. Suffice to say, the CNS biotech succeeded — and is now set with $100 million in cash that it secured late last year.
The biotech, which originally emerged from stealth back in December 2020 with an A and B round worth $113 million, made its presence known with some objectives in mind. Those included targets that would pit Neuron23 in the same space as pharmas like Denali and Biogen in Parkinson’s disease, and pursue a target that Bristol Myers Squibb has run with almost to the finish line.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.